Coronavirus Vaccine Shows Promising Early Results in China
A developed in appears to be safe and may protect people from the new coronavirus, researchers reported on Friday.
The early-stage trial, published in the Lancet, was conducted by researchers at several laboratories and included 108 participants aged 18 to 60. Those who received a single dose of the produced certain immune cells, called T cells, within two weeks. Antibodies needed for immunity peaked at 28 days after the inoculation.
“This is promising data, but it’s early data,” said Dr. Dan Barouch, director of research at Beth Israel Deaconess Medical Center in Boston, who was not involved in the work. “Over all, I would say this is good news.”
The trial is the first step in testing the vaccine and was intended mainly to verify its safety. Proof of its effectiveness will require trials in thousands, perhaps hundreds of thousands, more people.
A vaccine for the new is considered to be the best long-term solution for allowing countries to reopen their economies and return to normalcy. Multiple teams worldwide are racing to test various candidates.
On Monday, Moderna announced that its vaccine appeared to be safe and effective, based on results from eight people in its trial. And on Wednesday, Dr. Barouch and his colleagues published a study showing their prototype vaccine protected monkeys from infection.
Results of just one other human vaccine trial have been published in a scientific journal. That vaccine has now entered mid-stage human trials, the manufacturer, Sinovac Biotech Ltd., said on Friday.
The vaccine reported today was made with ...
More on: www.business-standard.com